GSK Reaffirms 2026 Guidance With 3%-5% Turnover Growth And 7%-9% Core EPS Growth, Eyes £40B+ Sales By 2031

GlaxoSmithKline plc Sponsored ADR

GlaxoSmithKline plc Sponsored ADR

GSK

0.00

2026 guidance and 2031 sales outlook reaffirmed • Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9% • 2031 sales outlook of more than £40 billion

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.